Revenue: As of FY2026 Q1, the actual value is USD 16.04 M.EPS: As of FY2026 Q1, the actual value is USD 2.82.EBIT: As of FY2026 Q1, the actual value is USD -4.941 M.<h4>Net Income</h4>Fortress Biotech-优先股 A’s consolidated net income attributable to common stockholders was $108.4 million for the first quarter ended March 31, 2026, significantly increasing from a net loss of - $12.7 million for the same period in 2025 .<h4>Revenue</h4>Consolidated net revenue totaled $16.0 million for the first quarter ended March 31, 2026, up from $13.1 million in the first quarter of 2025 . Journey Medical Product Revenue: Net product revenues from Journey Medical’s marketed dermatology products were $15.9 million for the first quarter of 2026, compared to $13.1 million for the first quarter ended March 31, 2025 . Cyprium Royalty Revenue: Cyprium recognized $0.1 million in royalty revenue on net sales of ZYCUBO® in the first quarter of 2026 .<h4>Operational Costs</h4><ul><li>Research and Development Expenses: Consolidated research and development expenses decreased to $0.5 million for the first quarter of 2026, from $3.9 million for the same period in 2025 .</li><li>Selling, General and Administrative Costs: Consolidated selling, general and administrative costs were $15.9 million for the first quarter of 2026, down from $25.7 million for the first quarter of 2025 .</li><li>Cost of Goods (excluding amortization): Cost of goods was $6.218 million for the first quarter of 2026, compared to $4.790 million for the first quarter of 2025 .</li><li>Amortization of Acquired Intangible Assets: Amortization expenses were $1.126 million for the first quarter of 2026, compared to $1.065 million for the first quarter of 2025 .</li></ul><h4>Operating Profit</h4>Loss from operations improved to - $7.739 million for the first quarter of 2026, from - $22.317 million for the first quarter of 2025 .<h4>Cash and Cash Equivalents</h4>Fortress Biotech-优先股 A’s consolidated cash and cash equivalents significantly increased to $255.8 million as of March 31, 2026, from $79.4 million as of December 31, 2025 . This includes $209.9 million attributable to Fortress Biotech-优先股 A and private subsidiaries, $2.4 million to Avenue, $16.3 million to Mustang Bio, and $27.2 million to Journey Medical as of March 31, 2026 .<h4>Unique Financial Metrics</h4><ul><li>Gain on Sale of Priority Review Voucher (PRV): Fortress Biotech-优先股 A recognized a gain of $158.873 million from the sale of a PRV, net of expenses, in the first quarter of 2026 . Cyprium Therapeutics closed the sale of its PRV for gross proceeds of $205 million in March 2026 .</li><li>Debt Reduction: Fortress Biotech-优先股 A made aggregate prepayments on its loan with Oaktree in March 2026, reducing the outstanding principal balance to $15.0 million . Long-term notes payable, net, decreased to $36.878 million as of March 31, 2026, from $52.417 million as of December 31, 2025 .</li></ul><h4>Outlook / Guidance</h4>Fortress Biotech-优先股 A expects increasing royalty revenue from ZYCUBO® and UNLOXCYT™, alongside potential milestone payments across its portfolio . AstraZeneca’s regulatory submissions in the EU and Japan for anselamimab (formerly CAEL-101) are anticipated to lead to potential future sales milestones for Fortress Biotech-优先股 A and approval milestones in the U.S. . Avenue plans to meet with the FDA in 2026 to discuss the design of a potential single pivotal trial for ATX-04 for Pompe disease .

Fortress Biotech Pref Share FBIOP 9.375 15/12/22 | 8-K: FY2026 Q1 Revenue: USD 16.04 M